Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5Cisplatin 5Gemcitabine 4trametinib 2repotrectinib 2pembrolizumab 2enzalutamide 2atezolizumab 2Surveys and Questionnaires 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Nivolumab 2Interviews as Topic 2Docetaxel 2Cetuximab 2Carboplatin 2vinflunine 1veliparib 1vadimezan 1toripalimab 1talazoparib 1sintilimab 1reolysin 1pixantrone 1pertuzumab 1peginterferon alfa-2a 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Clonidine × Tumor-Agnostic × Clear all
NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡